-
The vaccine has saved 94 million lives – but measles is spreading again
A disease we once believed belonged to the past is now resurging in both Europe and the United States. In the shadow of growing skepticism and declining vaccination coverage, measles – which has claimed millions of lives throughout history – is making a comeback.
-
Heart Monitoring in Breast Cancer – Essential or Excessive?
Papakonstantinou is working to refine how doctors identify which patients truly need intensive follow-up.
-
Venomaid's rapid test aims to find the right snake bite treatment
Every six seconds, someone on our planet suffers a snake bite, and each time, a race against the clock begins. What kind of snake was it, and which antivenom can help? Danish company Venomaid Diagnostics is working hard to develop solutions to a problem that claims countless lives, especially in tropical countries.
-
Trump in new push to lower drug prices
U.S. President Donald Trump announced on Sunday that he plans to sign an executive order to lower the cost of prescription drugs to the same levels paid in other wealthy countries — something he claims could reduce prices by 30 to 80 percent.
-
Who pays for Rebecca Doe – and all of us?
Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it
-
Ukraine war fuels rise of totally resistent bacteria
War-torn Ukraine is not just suffering from hostile attacks from a foreign aggressor, but also from the threat of a totally resistant and contagious bacteria.
-
Security flaw in Swedish breast cancer screening software – woman passed away
A lack of safeguard in Sectra's software led to a woman with breast cancer receiving an incorrect diagnosis. She later passed away. The software is used in 20 out of 21 regions in Sweden. It is also used in neighbouring Nordic countries. “Extremely serious,” says the Sectra CEO to Medtech Magazine.
-
AI detects tumor disease – via voice recording
A short voice recording along with facial images – both analyzed with an AI algorithm – can make it possible to detect the rare tumour disease acromegaly and initiate treatment at an early stage.
-
The business coach: “We need to learn from our mistakes”
The past year has been challenging for many biotech companies, with several comapanies facing financial stress and bankruptcy. To understand how entrepreneurs can navigate these tough times, Life Science Sweden spoke to Pia Keyser, a business coach at Umeå Biotech Incubator, who has worked with many companies in the industry.
-
Life science trends 2025 – The economy
Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. Today´s part of the series with trend insights in life science for 2025 is about the economy.
-
In search of Marcel Proust's lost health
A great writer, but also a weak person and a hypochondriac. That has been the usual image of Marcel Proust. But the pediatrician and literary scholar Carl Lindgren paints a partly different picture in a new book about the French master's life, health and attitude towards physicians.
-
Moderna fälls efter 20 000-kronorserbjudande till barn
Moderna kritiseras i Storbritannien för ett felaktigt meddelande där barn erbjöds 1 500 pund, motsvarande över 20 000 kronor, för deltagande i en klinisk studie av bolagets covid-vaccin.
-
Anna Törner: Yes, I Am Sick, But Not Weak
”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be respected, to not have their identity overshadowed by their condition”, writes Anna Törner in a column.
-
Thumbs down for lecanemab in the EU – “Very surprised”
The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), according to an announcement made by the Agency last week. Bioarctic’s CEO Gunilla Osswald describes the reactions after the announcement as a surprise and disappointment.
-
Healthcare study: Alzheimer’s blood test shows high accuracy
A blood test for identifying Alzheimer’s has now been tested in the general healthcare setting. According to the researchers, the test was 90% accurate in making a diagnosis.
-
Innovative start-up helps doctors, scientists and industry balance coagulation risks
For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thrombosis is an ongoing challenge. In the late 1980s, scientists at Maastricht University
-
Nocebo – the evil twin that makes you feel worse
The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala researcher Charlotte Blease, co-author of a book on the phenomenon.
-
”We need compatibility“
Penilla Gunther, founder of Fokus Patient and chair of the European Patient Safety Foundation, hopes that the forthcoming life science strategy will focus on efficient and secure management of patient data and equal access to medicines.
-
Marie Gårdmark: ”Interchangeable biological medicines – soon in a pharmacy near you?”
”Generic competition is an effective way to push down drug prices, but it has not worked equally well for biosimilars. Biosimilars require more time to gain market share compared to generics, and new biosimilars do not always lead to lower prices” writes Marie Gårdmark in a column.
-
Ozempic may benefit hip replacement surgery
The high-profile drug for type 2 diabetes and weight loss may be beneficial in other areas. One such area is for patients undergoing hip replacement surgery, a new study suggests.
-
The physician at the tech giant: “Observations in the emergency room made my mind up”
When Nasim Farrokhnia was in third grade at school in Tehran, the capital of Iran, her father gave her a book about Marie Curie, which soon became her favourite book. Perhaps her interest in science was born there and then, as science and new technology have since been a constant feature of her working life. Today, she is a Healthcare Manager in Microsoft’s Western Europe team.
-
Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients
In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.
-
Small robots to deliver pharmaceuticals to the body
Robots that can operate inside the body and a platform that combines ultrasound with AI. These are a couple of the technologies that have qualified for a list that aims to promote sustainable entrepreneurship.
-
Samuel Lagercrantz: The government’s performance in healthcare and life sciences so far
Since the change of government in Sweden, developments in the healthcare sector have shown promising signs, but the outlook in life sciences is less promising, writes Samuel Lagercrantz in an editorial.
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Redan prenumerant? Logga in
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
BREAKING